Soluble mediators as therapeutic targets in systemic lupus erythematosus: Cytokines, immunoglobulin receptors, and the complement system

Rheumatic Disease Clinics of North America

Volumn 32, Issue 1, 2006, Pages 103-119

  Kirou, Kyriakos A ^a,b   Salmon, Jane E ^a,b   Crow, Mary K ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ATLIZUMAB; BELIMUMAB; CHEMOKINE; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOKINE; FC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN RECEPTOR; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; SERINE PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTOIMMUNE DISEASE; AUTOIMMUNE THROMBOCYTOPENIA; BACTEREMIA; CLINICAL TRIAL; COMPLEMENT SYSTEM; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EPSTEIN BARR VIRUS; GLOMERULONEPHRITIS; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNE MEDIATED INJURY; NONHUMAN; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VIRUS INFECTION;

BIOLOGICAL RESPONSE MODIFIERS; COMPLEMENT ACTIVATION; CYTOKINES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECEPTORS, COMPLEMENT; RECEPTORS, IGG;

EID: 33344464477     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2005.12.001     Document Type: Review

References (102)

1. M.K. Crow, and K.A. Kirou Interferon-alpha in systemic lupus erythematosus Curr Opin Rheumatol 16 5 2004 541 547
2. R. Baccala, D.H. Kono, and A.N. Theofilopoulos Interferons as pathogenic effectors in autoimmunity Immunol Rev 204 2005 9 26
3. C. Gota, and L. Calabrese Induction of clinical autoimmune disease by therapeutic interferon-alpha Autoimmunity 36 8 2003 511 518
4. L.E. Ronnblom, G.V. Alm, and K.E. Oberg Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour J Intern Med 227 3 1990 207 210
5. A. Mathian, A. Weinberg, and M. Gallegos IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black × New Zealand White) F1 but not in BALB/c mice J Immunol 174 5 2005 2499 2506
6. M.L. Santiago-Raber, R. Baccala, and K.M. Haraldsson Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice J Exp Med 197 6 2003 777 788
7. D. Braun, P. Geraldes, and J. Demengeot Type I interferon controls the onset and severity of autoimmune manifestations in lpr mice J Autoimmun 20 1 2003 15 25
8. J.D. Hron, and S.L. Peng Type I IFN protects against murine lupus J Immunol 173 3 2004 2134 2142
9. A. Schwarting, K. Paul, and S. Tschirner Interferon-{beta}: a therapeutic for autoimmune lupus in MRL-Faslpr mice J Am Soc Nephrol 16 11 2005 3264 3272
10. A.A. Bengtsson, G. Sturfelt, and L. Truedsson Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies Lupus 9 9 2000 664 671
11. J.J. Hooks, H.M. Moutsopoulos, and S.A. Geis Immune interferon in the circulation of patients with autoimmune disease N Engl J Med 301 1 1979 5 8
12. E.C. Baechler, F.M. Batliwalla, and G. Karypis Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus Proc Natl Acad Sci USA 100 5 2003 2610 2615
13. L. Bennett, A.K. Palucka, and E. Arce Interferon and granulopoiesis signatures in systemic lupus erythematosus blood J Exp Med 197 6 2003 711 723
14. M.K. Crow, K.A. Kirou, and J. Wohlgemuth Microarray analysis of interferon-regulated genes in SLE Autoimmunity 36 8 2003 481 490
15. K.A. Kirou, C. Lee, and S. George Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus Arthritis Rheum 50 12 2004 3958 3967
16. K.A. Kirou, C. Lee, and S. George Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease Arthritis Rheum 52 5 2005 1491 1503
17. S. Blomberg, M.L. Eloranta, and B. Cederblad Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus Lupus 10 7 2001 484 490
18. L. Farkas, K. Beiske, and F. Lund-Johansen Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions Am J Pathol 159 1 2001 237 243
19. K.S. Peterson, J.F. Huang, and J. Zhu Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli J Clin Invest 113 12 2004 1722 1733
20. T.A. Stewart Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases Cytokine Growth Factor Rev 14 2 2003 139 154
21. A.N. Theofilopoulos, S. Koundouris, and D.H. Kono The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity Arthritis Res 3 3 2001 136 141
22. K.J. Moore, K. Yeh, and T. Naito TNF-alpha enhances colony-stimulating factor-1-induced macrophage accumulation in autoimmune renal disease J Immunol 157 1 1996 427 432
23. C.O. Jacob, and H.O. McDevitt Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis Nature 331 6154 1988 356 358
24. C. Gordon, G.E. Ranges, and J.S. Greenspan Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice Clin Immunol Immunopathol 52 3 1989 421 434
25. D.C. Brennan, M.A. Yui, and R.P. Wuthrich Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury J Immunol 143 11 1989 3470 3475
26. C.P. Maury, and A.M. Teppo Tumor necrosis factor in the serum of patients with systemic lupus erythematosus Arthritis Rheum 32 2 1989 146 150
27. C. Gabay, N. Cakir, and F. Moral Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity J Rheumatol 24 2 1997 303 308
28. D. Malide, P. Russo, and M. Bendayan Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients Hum Pathol 26 5 1995 558 564
29. R. Herrera-Esparza, O. Barbosa-Cisneros, and R. Villalobos-Hurtado Renal expression of IL-6 and TNFalpha genes in lupus nephritis Lupus 7 3 1998 154 158
30. A. Studnicka-Benke, G. Steiner, and P. Petera Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus Br J Rheumatol 35 11 1996 1067 1074
31. P.J. Charles, R.J. Smeenk, and J. De Jong Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials Arthritis Rheum 43 11 2000 2383 2390
32. N. Shakoor, M. Michalska, and C.A. Harris Drug-induced systemic lupus erythematosus associated with etanercept therapy Lancet 359 9306 2002 579 580
33. M. Aringer, W.B. Graninger, and G. Steiner Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study Arthritis Rheum 50 10 2004 3161 3169
34. G. Sturfelt, P. Roux-Lombard, and F.A. Wollheim Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus Br J Rheumatol 36 12 1997 1283 1289
35. F. Moosig, R. Zeuner, and C. Renk IL-1RA in refractory systemic lupus erythematosus Lupus 13 8 2004 605 606
36. B. Ostendorf, C. Iking-Konert, and K. Kurz Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis Ann Rheum Dis 64 4 2005 630 633
37. K.H. Sun, C.L. Yu, and S.J. Tang Monoclonal anti-double-stranded DNA autoantibody stimulates the expression and release of IL-1beta, IL-6, IL-8, IL-10 and TNF-alpha from normal human mononuclear cells involving in the lupus pathogenesis Immunology 99 3 2000 352 360
38. E. Tackey, P.E. Lipsky, and G.G. Illei Rationale for interleukin-6 blockade in systemic lupus erythematosus Lupus 13 5 2004 339 343
39. B.K. Finck, B. Chan, and D. Wofsy Interleukin 6 promotes murine lupus in NZB/NZW F1 mice J Clin Invest 94 2 1994 585 591
40. M. Mihara, N. Takagi, and Y. Takeda IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice Clin Exp Immunol 112 3 1998 397 402
41. M. Linker-Israeli, R.J. Deans, and D.J. Wallace Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis J Immunol 147 1 1991 117 123
42. G. Grondal, I. Gunnarsson, and J. Ronnelid Cytokine production, serum levels and disease activity in systemic lupus erythematosus Clin Exp Rheumatol 18 5 2000 565 570
43. E.M. Davas, A. Tsirogianni, and I. Kappou Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus Clin Rheumatol 18 1 1999 17 22
44. B.J. Ripley, B. Goncalves, and D.A. Isenberg Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia Ann Rheum Dis 64 6 2005 849 853
45. N. Nishimoto, K. Yoshizaki, and N. Miyasaka Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial Arthritis Rheum 50 6 2004 1761 1769
46. S. Yokota, T. Miyamae, and T. Imagawa Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis Arthritis Rheum 52 3 2005 818 825
47. M. Mihara, K. Kasutani, and M. Okazaki Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family Int Immunopharmacol 5 12 2005 1731 1740
48. M.N. Sharif, I. Tassiulas, and Y. Hu IFN-alpha priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis J Immunol 172 10 2004 6476 6481
49. L. Llorente, W. Zou, and Y. Levy Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus J Exp Med 181 3 1995 839 844
50. J. Ronnelid, A. Tejde, and L. Mathsson Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE Ann Rheum Dis 62 1 2003 37 42
51. H. Ishida, T. Muchamuel, and S. Sakaguchi Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice J Exp Med 179 1 1994 305 310
52. C.T. Ravirajan, Y. Wang, and L.A. Matis Effect of neutralizing antibodies to IL-10 and C5 on the renal damage caused by a pathogenic human anti-dsDNA antibody Rheumatology (Oxford) 43 4 2004 442 447
53. Z. Yin, G. Bahtiyar, and N. Zhang IL-10 regulates murine lupus J Immunol 169 4 2002 2148 2155
54. F.A. Houssiau, C. Lefebvre, and M. Vanden Berghe Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity Lupus 4 5 1995 393 395
55. Y.B. Park, S.K. Lee, and D.S. Kim Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus Clin Exp Rheumatol 16 3 1998 283 288
56. M. Lazarus, A.H. Hajeer, and D. Turner Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus J Rheumatol 24 12 1997 2314 2317
57. H. Schotte, M. Gaubitz, and P. Willeke Interleukin-10 promoter microsatellite polymorphisms in systemic lupus erythematosus: association with the anti-Sm immune response Rheumatology (Oxford) 43 11 2004 1357 1363
58. L. Llorente, Y. Richaud-Patin, and C. Garcia-Padilla Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus Arthritis Rheum 43 8 2000 1790 1800
59. L. Lit, C. Wong, and L. Tam Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus Ann Rheum Dis 65 2 2006 209 215
60. M.C. Park, Y.B. Park, and S.K. Lee Elevated interleukin-18 levels correlated with disease activity in systemic lupus erythematosus Clin Rheumatol 23 3 2004 225 229
61. C.K. Wong, E.K. Li, and C.Y. Ho Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus Rheumatology (Oxford) 39 10 2000 1078 1081
62. S. Lee, H. Kaneko, and I. Sekigawa Circulating interleukin-16 in systemic lupus erythematosus Br J Rheumatol 37 12 1998 1334 1337
63. N. Yajima, T. Kasama, and T. Isozaki Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations Arthritis Rheum 52 6 2005 1670 1675
64. W. Stohl A therapeutic role for BLyS antagonists Lupus 13 5 2004 317 322
65. J.A. Gross, J. Johnston, and S. Mudri TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease Nature 404 6781 2000 995 999
66. J. Zhang, V. Roschke, and K.P. Baker Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus J Immunol 166 1 2001 6 10
67. G.S. Cheema, V. Roschke, and D.M. Hilbert Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases Arthritis Rheum 44 6 2001 1313 1319
68. Human Genome Sciences Press release: human genome sciences reports results of a phase 2 clinical trial of lymphostat-B™ in patients with systemic lupus erythematosus Available at: http://www.hgsi.com/news/press/05-10- 05_LSB_Phase_2_Results.htm Accessed January 10, 2006
69. J.V. Ravetch, and S. Bolland IgG Fc receptors Annu Rev Immunol 19 2001 275 290
70. J.V. Ravetch, and R.A. Clynes Divergent roles for Fc receptors and complement in vivo Annu Rev Immunol 16 1998 421 432
71. T. Takai, M. Ono, and M. Hikida Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice Nature 379 6563 1996 346 349
72. R. Clynes, J.S. Maizes, and R. Guinamard Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors J Exp Med 189 1 1999 179 185
73. S. Bolland, and J.V. Ravetch Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis Immunity 13 2 2000 277 285
74. M. Marino, M. Ruvo, and S. De Falco Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide Nat Biotechnol 18 7 2000 735 739
75. J.B. Bussel Fc receptor blockade and immune thrombocytopenic purpura Semin Hematol 37 3 2000 261 266
76. D.B. Cines, and V.S. Blanchette Immune thrombocytopenic purpura N Engl J Med 346 13 2002 995 1008
77. L. Pricop, P. Redecha, and J.L. Teillaud Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines J Immunol 166 1 2001 531 537
78. A. Samuelsson, T.L. Towers, and J.V. Ravetch Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor Science 291 5503 2001 484 486
79. V. Ghetie, and E.S. Ward Multiple roles for the major histocompatibility complex class I- related receptor FcRn Annu Rev Immunol 18 2000 739 766
80. S. Sell, and J.L. Fahey Relationship between gamma-globulin metabolism and low serum gamma-globulin in germfree mice J Immunol 93 1964 81 87
81. R.P. Junghans, and C.L. Anderson The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor Proc Natl Acad Sci USA 93 11 1996 5512 5516
82. Z. Yu, and V.A. Lennon Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases N Engl J Med 340 3 1999 227 228
83. P. Sondermann, R. Huber, and U. Jacob Crystal structure of the soluble form of the human fcgamma-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 A resolution EMBO J 18 5 1999 1095 1103
84. K.F. Maxwell, M.S. Powell, and M.D. Hulett Crystal structure of the human leukocyte Fc receptor, Fc gammaRIIa Nat Struct Biol 6 5 1999 437 442
85. R.A. Clynes, T.L. Towers, and L.G. Presta Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nat Med 6 4 2000 443 446
86. A.K. Abbas, A.H. Lichtman, and J.S. Pober Cellular and molecular immunity 2003 WB Saunders Philadelphia 326 342
87. B.Z. Schmidt, and H.R. Colten Complement: a critical test of its biological importance Immunol Rev 178 2000 166 176
88. D.T. Fearon Seeking wisdom in innate immunity Nature 388 6640 1997 323 324
89. T.E. Hugli Structure and function of C3a anaphylatoxin Curr Top Microbiol Immunol 153 1990 181 208
90. M.K. Liszewski, T.C. Farries, and D.M. Lublin Control of the complement system Adv Immunol 61 1996 201 283
91. V.M. Holers, T. Kinoshita, and H. Molina The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function Immunol Today 13 6 1992 231 236
92. A.P. Manderson, M. Botto, and M.J. Walport The role of complement in the development of systemic lupus erythematosus Annu Rev Immunol 22 2004 431 456
93. L.A. Hebert, D.J. Birmingham, and X.P. Shen Stimulating erythropoiesis increases complement receptor expression on primate erythrocytes Clin Immunol Immunopathol 62 3 1992 301 306
94. K. Steinsson, K. Erlendsson, and H. Valdimarsson Successful plasma infusion treatment of a patient with C2 deficiency and systemic lupus erythematosus: clinical experience over forty-five months Arthritis Rheum 32 7 1989 906 913
95. H.F. Weisman, T. Bartow, and M.K. Leppo Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium Trans Assoc Am Physicians 103 1990 64 72
96. C. Atkinson, H. Song, and B. Lu Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection J Clin Invest 115 9 2005 2444 2453
97. H. Song, C. He, and C. Knaak Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation J Clin Invest 111 12 2003 1875 1885
98. R.J. Quigg, Y. Kozono, and D. Berthiaume Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor J Immunol 160 9 1998 4553 4560
99. Y. Wang, Q. Hu, and J.A. Madri Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5 Proc Natl Acad Sci USA 93 16 1996 8563 8568
100. P. Hillmen, C. Hall, and J.C. Marsh Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria N Engl J Med 350 6 2004 552 559
101. M.C. Carroll The role of complement and complement receptors in induction and regulation of immunity Annu Rev Immunol 16 1998 545 568
102. H. Watanabe, G. Garnier, and A. Circolo Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B J Immunol 164 2 2000 786 794